Literature DB >> 3744549

Adjuvant activity of 6-O-acyl-muramyldipeptides to enhance primary cellular and humoral immune responses in guinea pigs: dose-response and local reactions observed with selected compounds.

M Tsujimoto, S Kotani, T Shiba, S Kusumoto.   

Abstract

6-O-(2-Tetradecylhexadecanoyl)-N-acetylmuramyl-L-alanyl-D-isoglutamine (B3O-MDP) and 6-O-(3-hydroxy-2-docosylhexacosanoyl)-MDP (BH48-MDP) were examined for immunopotentiating activity in stimulating the primary immune responses of guinea pigs to ovalbumin and for adverse reactions at the injection site and in the regional lymph nodes when administered in combination with several nonirritating vehicles. B30-MDP was found to potently stimulate both humoral and cellular immune responses, the latter by induction of delayed-type hypersensitivity, irrespective of the administration vehicle examined (liposomes, a squalene in water emulsion, Intralipid, phosphate-buffered saline, and Nikkol HCO-60 glucose solution), although the minimum effective dose was dependent on the vehicle used. Reactions in the footpad receiving the injection were negligible. Noticeable local reaction consisted of swelling of the lymph nodes in the region of the injection, but the swelling was only noted with higher doses and subsided 3 to 4 weeks after immunization, unlike the persistent swelling caused by the administration of water-in-mineral oil emulsions with or without B30-MDP. BH48-MDP and its L-serine analog, BH48-MDP(L-Ser), which has L-serine in place of L-alanine in MDP, in combination with the squalene-in-water emulsion, also intensely stimulated both cellular and humoral antiovalbumin immune responses, but the effects of these compounds seemed to be influenced to a greater degree by the vehicles than by B30-MDP. Thus, B30-MDP was chosen from a series of a 6-O-acyl derivatives of MDP as the most promising candidate for possible application in practical vaccines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3744549      PMCID: PMC260820          DOI: 10.1128/iai.53.3.517-521.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  4 in total

1.  A new model of experimental arthritis induced by an aqueous form of synthetic adjuvant in immunodeficient rate (SHR and nude rats).

Authors:  O Kohashi; Y Kohashi; S Kotani; A Osawa
Journal:  Ryumachi       Date:  1981

2.  Cloning of a serotype-specific antigen from Pasteurella haemolytica A1.

Authors:  C Gonzalez-Rayos; R Y Lo; P E Shewen; T J Beveridge
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

3.  Granuloma formation by muramyl dipeptide associated with branched fatty acids, a structure probably essential for tubercle formation by Mycobacterium tuberculosis.

Authors:  K Emori; S Nagao; N Shigematsu; S Kotani; M Tsujimoto; T Shiba; S Kusumoto; A Tanaka
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

4.  Necrotic inflammatory reaction induced by muramyl dipeptide in guinea pigs sensitized by tubercle bacilli.

Authors:  S Nagao; A Tanaka
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

  4 in total
  4 in total

1.  Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; L Q Tam; S P Chang; S E Case; C Hashiro; W A Siddiqui; T Shiba; S Kusumoto; S Kotani
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

2.  Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects.

Authors:  Z Zídek
Journal:  Agents Actions       Date:  1992-05

3.  Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.

Authors:  Tomohiro Watanabe; Naoki Asano; Peter J Murray; Keiko Ozato; Prafullakumar Tailor; Ivan J Fuss; Atsushi Kitani; Warren Strober
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

4.  A synthetic adjuvant effective in inducing antitumor immunity.

Authors:  T Kataoka; T Tokunaga
Journal:  Jpn J Cancer Res       Date:  1988-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.